Two cases of chronic hepatitis B with emergence of lamivudine-resistant virus during long-term therapy

Shin Ichi Fujioka, Hiroyuki Shimomura, Kozo Fujio, Fusao Ikeda, Masanobu Miyake, Yasushi Ishii, Mamoru Itoh, Kosaku Sakaguchi, Takao Tsuji

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

Lamivudine is a potent antiviral drug for chronic hepatitis B, however the emergence of mutant virus resistant to lamivudine has been reported in patients with long-term administration of this drug. Here we report two patients with chronic hepatitis B treated with 48- and 52-weeks administration of lamivudine whose serum hepatitis B virus (HBV) DNA became positive during therapy. The amino acid sequence of the polymerase region of HBV from these patients revealed a YI/VDD mutation of the YMDD motif and a 223Leu to Met mutation, which were reported previously in immune suppressed patients during long-term lamivudine therapy for hepatitis B. After the cessation of therapy, serum HBV-DNA returned to wild-type immediately. Emergence of mutant virus resistant to lamivudine should be monitored during long-term lamivudine therapy.

Original languageEnglish
Pages (from-to)97-104
Number of pages8
JournalHepatology Research
Volume13
Issue number2
Publication statusPublished - Jan 1 1999

Keywords

  • Antiviral therapy
  • Hepatitis B virus
  • Hronic hepatitis
  • Lamivudine
  • Mutation

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Two cases of chronic hepatitis B with emergence of lamivudine-resistant virus during long-term therapy'. Together they form a unique fingerprint.

Cite this